Biontech announces second quarter 2023 financial results and corporate update

Significant pipeline advancement highlighted by the initiation of bnt316/onc-392 phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio positive data updates across multiple technology platforms including adc candidate bnt323/db-1303, anti-ctla4 monoclonal antibody candidate bnt316/onc-392 and car-t candidate bnt211 preparation for launch of omicron xbb.1.5-adapted monovalent covid-19 vaccine as recommended by the u.s. food and drug administration (fda), european medicines agency (ema) and other health authorities; deliveries expected to start as early as september, subject to regulatory approval reiterates covid-19 vaccine revenue guidance of approximately €5 billion in 2023 first half1 of 2023 revenues of €1.4 billion2, net profit of €311.8 million and fully diluted earnings per share of €1.28 ($1.383) conference call and webcast scheduled for august 7, 2023, at 8:00 am edt (2:00 pm cest) mainz, germany, august 7, 2023 (globe newswire) -- biontech se (nasdaq: bntx, “biontech” or “the company”) today reported financial results for the three and six months ended june 30, 2023, and provided an update on its corporate progress. “we are progressing our oncology pipeline into late-stage development, having launched a pivotal phase 3 trial and preparing for additional trials with registrational potential in the coming months,” said prof.
BNTX Ratings Summary
BNTX Quant Ranking